Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in Europe and Latin America

The mRNA vaccines against SARS-CoV-2 have protected billions of people worldwide, but the novel variants of concern (VoC) could escape the vaccine-acquired immunity. P95 participated in the safety monitoring of the phase 2b/3 HERALD study to weigh the efficacy and safety of the unmodified mRNA COVID-19 vaccine candidate, CVnCoV. In this 40,000-person trial across ten countries in Europe and Latin America, CVnCoV was found to be 48% efficacious against symptomatic COVID-19. Systemic adverse events were more frequent in the CVnCoV group than in the placebo group. Judging the fast-changing COVID-19 vaccine landscape with the emergence of VoC, the researchers recommended halting activities on CVnCoV and aiming to develop next-generation vaccine candidates. 

You can read the published manuscript here: